Safety assurance for biologics manufactured in mammalian cell cultures: a multitiered strategy
Related Experiment Video
Updated: May 11, 2026

Microbial Control and Monitoring Strategies for Cleanroom Environments and Cellular Therapies
Published on: March 17, 2023
1Bioproduct Research and Development, Lilly Research Laboratories, Eli Lilly and Company, DC3941, Lilly Corporate Center, Indianapolis, IN, 46285, USA, chen_dayue@lilly.com.
Abstract:
Contamination by viral and microbial agents is a serious risk for biopharmaceuticals produced by mammalian cell culture processes. In order to effectively mitigate the risk and minimize the occurrence of such contamination events, a multi-tiered approach has been adopted to safeguard the manufacturing processes from A to Z. The multi-tiered approach consists of three separate, yet complementary, elements: (1) control and testing of raw materials in general, and animal sourced materials (ASM) in particular; (2) in-process and release testing for adventitious agents with emphasis on viruses based on risk assessment; and (3) demonstration of an adequate, robust, and consistent viral clearance capability by the downstream purification process. The implementations of these measures will be described in the context of regulatory compliance and GMP manufacturing.
Related Concept Videos
Upstream Processing
Drug Products: Biologics, Biosimilars and Interchangeables
Bioreactor Controls-III
Scale-Up Processes
Cell Lines
Bioreactor Design and Operational System

